Publications by authors named "Tina E French"
J Am Coll Cardiol
September 2024
Article Synopsis
- This study compares the cardiovascular effectiveness of different second-line antihyperglycemic agents (SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas) in patients with type 2 diabetes and cardiovascular disease.
- Using data from over 1.4 million patients across multiple databases, the researchers analyzed the risk of major adverse cardiovascular events (MACE) over a follow-up period of several years.
- Results indicated that SGLT2 inhibitors and GLP-1 receptor agonists had significantly lower risks of MACE compared to DPP-4 inhibitors and sulfonylureas, pointing to their potential superiority as treatment options for
Article Synopsis
- * The study analyzed data from over 1.4 million patients treated with various second-line diabetes medications, using advanced statistical methods to compare outcomes and risks of heart issues.
- * Findings indicated that both SGLT2 inhibitors and GLP-1 receptor agonists reduce the risk of cardiovascular events compared to DPP-4 inhibitors and sulfonylureas, but no significant differences were found between SGLT2is and GLP1-RAs themselves regarding heart risks.
Article Synopsis
- The study aimed to evaluate the adoption of second-line antihyperglycaemic medications among type 2 diabetes patients using metformin, analyzing data from 10 US and 7 international health databases.
- A total of 4.8 million participants were included, focusing on the trends in initiating additional diabetes treatments over the years 2011 to 2021.
- Results showed significant growth in the use of cardioprotective drugs (like GLP-1 receptor agonists and SGLT2 inhibitors) as second-line options, with initiation rates varying widely across countries and databases.
